Natural History Study of Participants With Sanfilippo Syndrome Type IIIC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-10

Study Completion Date

2027-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is planned to document, through retrospective and prospective data collection, syndrome progression in children and young adults with MPS IIIC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Natural History Study of Sanfilippo Syndrome Type D

NCT05648851

Sanfilippo Syndrome Type D

COMPLETED

The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)

NCT05705674

Sanfilippo Syndrome MPS3

RECRUITING

Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

NCT01509768

Sanfilippo Syndrome Type B

COMPLETED

Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

NCT02293408

MPS IIIB (Sanfilippo B Syndrome)

TERMINATED

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)

NCT05523206

Mucopolysaccharidosis III-A

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, natural history study of subjects with Sanfilippo syndrome type C or MPS IIIC. This study will combine a retrospective review of medical records and an ongoing collection of clinical data on an observational basis. Real-world data will be collected at home using a recording device.

Participants will be asked to attend clinic visits in person on a yearly basis. In clinic visits will include neurocognitive, developmental, behavioral, biochemical, imaging measures as well as retrospective medical record analysis.

At 6-month intervals between clinic visits, participants will be contacted remotely for some safety assessments (e.g., collecting information about concomitant medications, concurrent illnesses, and procedure-related adverse events \[AEs\] and serious AEs \[SAEs\] since last clinic visit).

At 6-month intervals, caregivers will complete questionnaires and record home video assessments using a dedicated, compliant study application (app) called C-RARE (Recording Application for Real-World Evidence). The C-RARE app consists of 9 tasks of Activities of Daily Living and socialization as well as three parent reported Sanfilippo specific questionnaires.

The objectives of this study are:

* To enhance the understanding of the natural history and progression of MPS IIIC syndrome on behavior, cognitive abilities, mobility, vision, hearing, speech, and expressive and receptive language
* To define and categorize clinical endpoints that may be used in future clinical trials

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sanfilippo Syndrome Type C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Retrospective and prospective observational study of patients living with MPS IIIC

Cohort 1: These participants will be a part of the retrospective and prospective Natural History Study, including the C-RARE video assessments. In clinic visits will include: neurocognitive, developmental and behavioral clinical outcome assessments as well as biochemical sample analysis, imaging measures and retrospective medical record review. Participants will record daily living activities through the C-RARE app on their mobile device.

No interventions assigned to this group

Remote video recording study and retrospective medical chart review of patients living with MPS IIIC

Cohort 2: These participants will not attend in clinic visits. They will be a part of the C-RARE and retrospective medical chart review analysis. 35 patients with a confirmed diagnosis of MPS IIIC from English, Spanish and Portuguese speaking households will be recruited for this portion of the study.

No interventions assigned to this group

Retrospective medical chart review of MPS IIIC patients either living or deceased

Cohort 3: Deceased or living medical record analysis only of patients with MPS IIIC. Living patients will not be participating in cohort 1 clinical study or cohort 2 C-RARE study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Confirmed diagnosis of Sanfilippo syndrome type C disease by all of the following:

* Deficiency in heparan-alpha-glucosaminide N-acetyltransferase enzyme activity
* Has presented with signs/symptoms consistent with Sanfilippo syndrome type C, or, for individuals who have not presented with signs/symptoms of disease (eg, siblings of known patients), the determination of eligibility will be at the discretion of the Sponsor in conjunction with the site Investigator
* Genomic DNA analysis demonstrating homozygous or compound heterozygous, pathogenic and/or potentially pathogenic variants in the HGSNAT gene
* Accumulated GAG HS in urine
* Written informed consent from parent or legal guardian and assent from patient, if required
* Parent/legal guardian willing to accompany the patient to all study visits
* Ability to comply with protocol requirements, in the opinion of the Investigator
* Negative urine pregnancy test at screening (nonsterile females of childbearing potential only).

Functional abilities:

* Able to take food or liquid by mouth, able to walk with or without assistance.
* Has an age equivalent on the Vineland Adaptive Behavior Scales (VABS) of ≥1 year.

Exclusion Criteria

Patients who meet any of the following criteria will not be eligible to participate in the study:

* Have received an investigational drug within 30 days prior to the Baseline Visit
* Concomitant illness or medical condition or extenuating circumstance that, in the opinion of the Investigator, might compromise the patient's ability to comply with protocol requirements, the patient's well-being or safety, or the interpretability of the patient's clinical data
* The presence of significant non-MPS IIIC-related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study

Minimum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No